Literature DB >> 20861168

Association of the novel non-AT1, non-AT2 angiotensin binding site with neuronal cell death.

Mamoon Rashid1, Thiruma V Arumugam, Vardan T Karamyan.   

Abstract

We have discovered a non-AT(1), non-AT(2) angiotensin binding site in rodent and human brain membranes, which, based on its pharmacological/biochemical properties and tissue distribution, is different from angiotensin receptors and key proteases processing angiotensins. In this study, the novel angiotensin binding site was localized to a specific brain cell type by using radioligand receptor binding assays. Our results indicate that the novel binding site is expressed in mouse primary cortical neuronal membranes but not in primary cortical astroglial and bEnd.3 brain capillary endothelial cell membranes. Whole-cell binding assays in neurons showed that the binding site faces the outer side of the plasma membrane. Consistent with our previous observations, the novel binding site was unmasked by the sulfhydryl reagent p-chloromercuribenzoate. This effect had a bell-shaped curve and was reversed by reduced glutathione, indicating that the function of the binding site might be regulated by the redox state of the environment. Density of the novel binding site measured by saturation binding assays was significantly increased in neuronal membranes of cells challenged in four in vitro models of cell death (oxygen-glucose deprivation, sodium azide-induced hypoxia, N-methyl-D-aspartate neurotoxicity, and hydrogen peroxide neurotoxicity). In addition, our in vivo data from developing mouse brains showed that the density of the novel angiotensin binding site changes similarly to the pattern of neuronal death in maturating brain. This is the first time that evidence is provided on the association of the novel angiotensin binding site with neuronal death, and future studies directed toward understanding of the functions of this protein are warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861168     DOI: 10.1124/jpet.110.171439

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Peptidase neurolysin is an endogenous cerebroprotective mechanism in acute neurodegenerative disorders.

Authors:  Vardan T Karamyan
Journal:  Med Hypotheses       Date:  2019-07-13       Impact factor: 1.538

2.  Peptidase neurolysin functions to preserve the brain after ischemic stroke in male mice.

Authors:  Srinidhi Jayaraman; Abdullah Al Shoyaib; Joanna Kocot; Heidi Villalba; Faisal F Alamri; Mamoon Rashid; Naomi J Wangler; Ekram A Chowdhury; Nadezhda German; Thiruma V Arumugam; Thomas J Abbruscato; Vardan T Karamyan
Journal:  J Neurochem       Date:  2019-10-22       Impact factor: 5.372

3.  Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Authors:  Naomi J Wangler; Kira L Santos; Ines Schadock; Fred K Hagen; Emanuel Escher; Michael Bader; Robert C Speth; Vardan T Karamyan
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

4.  Pharmacological characterization of a novel non-AT1, non-AT2 angiotensin binding site identified as neurolysin.

Authors:  Jamala D Swindle; Kira L Santos; Robert C Speth
Journal:  Endocrine       Date:  2013-02-15       Impact factor: 3.633

Review 5.  Neurolysin: From Initial Detection to Latest Advances.

Authors:  Frédéric Checler; Emer S Ferro
Journal:  Neurochem Res       Date:  2018-08-29       Impact factor: 3.996

6.  In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.

Authors:  Li Yang; Mohammad R Islam; Vardan T Karamyan; Thomas J Abbruscato
Journal:  Brain Res       Date:  2015-03-20       Impact factor: 3.252

7.  Structure-activity relationship studies of functionalized aromatic peptidomimetics as neurolysin activators.

Authors:  Md Shafikur Rahman; Shiva Hadi Esfahani; Saeideh Nozohouri; Shikha Kumari; Joanna Kocot; Yong Zhang; Thomas J Abbruscato; Vardan T Karamyan; Paul C Trippier
Journal:  Bioorg Med Chem Lett       Date:  2022-03-12       Impact factor: 2.823

8.  The effects of para-chloromercuribenzoic acid and different oxidative and sulfhydryl agents on a novel, non-AT1, non-AT2 angiotensin binding site identified as neurolysin.

Authors:  Kira L Santos; Megan A Vento; John W Wright; Robert C Speth
Journal:  Regul Pept       Date:  2013-03-16

9.  Identification and Characterization of Two Structurally Related Dipeptides that Enhance Catalytic Efficiency of Neurolysin.

Authors:  Srinidhi Jayaraman; Joanna Kocot; Shiva Hadi Esfahani; Naomi J Wangler; Arzu Uyar; Yehia Mechref; Paul C Trippier; Thomas J Abbruscato; Alex Dickson; Hideki Aihara; David A Ostrov; Vardan T Karamyan
Journal:  J Pharmacol Exp Ther       Date:  2021-08-13       Impact factor: 4.030

10.  Neurolysin substrates bradykinin, neurotensin and substance P enhance brain microvascular permeability in a human in vitro model.

Authors:  Abraham J Al-Ahmad; Iqra Pervaiz; Vardan T Karamyan
Journal:  J Neuroendocrinol       Date:  2021-01-28       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.